-- 上海ヘンリウスバイオテック（香港証券取引所：2696）は、火曜日に香港証券取引所に提出した書類の中で、中国国家薬品監督管理局からHLX05-Nの第1相臨床試験の承認を取得したと発表した。 この薬剤は、転移性大腸がんの治療薬として研究されている。
Related Articles
Research
Rothschild & Co Redburn Upgrades Rollins to Buy From Neutral, Adjusts PT to $66 From $51.90
Rollins (ROL) has an average rating of overweight and mean price target of $65.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ROL
Research
Arete Research Upgrades Fortinet to Buy From Sell, Adjusts Price Target to $104 From $83
Fortinet (FTNT) has an average rating of hold and mean price target of $88.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$FTNT
Research
BNP Paribas Downgrades GE Vernova to Neutral From Outperform, Adjusts PT to $1,190 From $765
GE Vernova (GEV) has an average rating of overweight and mean price target of $1,179.31, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GEV